KR102654033B1 - 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 - Google Patents

가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 Download PDF

Info

Publication number
KR102654033B1
KR102654033B1 KR1020177018958A KR20177018958A KR102654033B1 KR 102654033 B1 KR102654033 B1 KR 102654033B1 KR 1020177018958 A KR1020177018958 A KR 1020177018958A KR 20177018958 A KR20177018958 A KR 20177018958A KR 102654033 B1 KR102654033 B1 KR 102654033B1
Authority
KR
South Korea
Prior art keywords
cells
adcc
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177018958A
Other languages
English (en)
Korean (ko)
Other versions
KR20170089003A (ko
Inventor
치앙 제이 리
샤이암 언니라만
Original Assignee
1글로브 바이오메디칼 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1글로브 바이오메디칼 씨오., 엘티디. filed Critical 1글로브 바이오메디칼 씨오., 엘티디.
Publication of KR20170089003A publication Critical patent/KR20170089003A/ko
Application granted granted Critical
Publication of KR102654033B1 publication Critical patent/KR102654033B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020177018958A 2014-12-08 2015-12-08 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 Active KR102654033B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462089097P 2014-12-08 2014-12-08
US62/089,097 2014-12-08
US201562200557P 2015-08-03 2015-08-03
US62/200,557 2015-08-03
PCT/US2015/064572 WO2016094456A1 (en) 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Publications (2)

Publication Number Publication Date
KR20170089003A KR20170089003A (ko) 2017-08-02
KR102654033B1 true KR102654033B1 (ko) 2024-04-02

Family

ID=56108081

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018958A Active KR102654033B1 (ko) 2014-12-08 2015-12-08 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도

Country Status (11)

Country Link
US (2) US12247062B2 (cg-RX-API-DMAC7.html)
EP (1) EP3230311B1 (cg-RX-API-DMAC7.html)
JP (2) JP7095992B2 (cg-RX-API-DMAC7.html)
KR (1) KR102654033B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108718B (cg-RX-API-DMAC7.html)
AU (1) AU2015360642B2 (cg-RX-API-DMAC7.html)
CA (1) CA2968987C (cg-RX-API-DMAC7.html)
NZ (1) NZ732073A (cg-RX-API-DMAC7.html)
RU (1) RU2725807C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201704124YA (cg-RX-API-DMAC7.html)
WO (1) WO2016094456A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
JP7095992B2 (ja) 2014-12-08 2022-07-05 1グローブ バイオメディカル カンパニー, リミテッド 可溶性ユニバーサルadcc増強合成融合遺伝子およびペプチド技術ならびにその使用
CN112512573B (zh) * 2018-05-23 2026-02-27 百提威生技股份有限公司 双特异性t细胞衔接蛋白及其用途
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
AU2021301788A1 (en) * 2020-06-30 2023-01-19 Gaia Biomedicine Inc. Method for stabilizing binding of NK cell and antibody, and use thereof
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
IE920716A1 (en) * 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
CA2447695C (en) * 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
AU2004215133B2 (en) * 2003-02-27 2010-10-14 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
BRPI0507649A (pt) * 2004-02-16 2007-07-10 Micromet Ag molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2008091682A2 (en) * 2007-01-23 2008-07-31 Zymogenetics, Inc. Soluble fc gamma r1a for reducing inflammation
US8043621B2 (en) * 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
AU2011349049B2 (en) * 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
BR112014014418A2 (pt) * 2011-12-15 2019-09-24 Nat Res Council Canada proteínas de fusão fc de receptor igf solúvel e usos das mesmas
JP6407726B2 (ja) * 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH 長寿命ポリペプチド結合分子
JP7095992B2 (ja) 2014-12-08 2022-07-05 1グローブ バイオメディカル カンパニー, リミテッド 可溶性ユニバーサルadcc増強合成融合遺伝子およびペプチド技術ならびにその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein

Also Published As

Publication number Publication date
US20220235115A1 (en) 2022-07-28
JP7095992B2 (ja) 2022-07-05
EP3230311B1 (en) 2022-01-26
CN107108718B (zh) 2022-07-22
US20170362299A1 (en) 2017-12-21
WO2016094456A1 (en) 2016-06-16
US12247062B2 (en) 2025-03-11
CA2968987A1 (en) 2016-06-16
JP2018502068A (ja) 2018-01-25
JP2021035994A (ja) 2021-03-04
NZ732073A (en) 2019-04-26
CA2968987C (en) 2022-05-10
EP3230311A4 (en) 2018-05-30
EP3230311A1 (en) 2017-10-18
RU2017124141A (ru) 2019-01-10
CN107108718A (zh) 2017-08-29
AU2015360642A1 (en) 2017-06-08
AU2015360642B2 (en) 2019-04-04
KR20170089003A (ko) 2017-08-02
RU2725807C2 (ru) 2020-07-06
SG11201704124YA (en) 2017-06-29
RU2017124141A3 (cg-RX-API-DMAC7.html) 2019-06-19

Similar Documents

Publication Publication Date Title
US20220235115A1 (en) Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof
US11667693B2 (en) Synthetic biology-based ADCC technology
KR20220041161A (ko) Mage-a에 특이적으로 결합하는 항원 결합 단백질
EP4442701A1 (en) Combination of molecular switch regulation type chimeric antigen receptor cell and antibody, and use thereof
EP4445912A1 (en) P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereof
CN120152735A (zh) Adgre2嵌合受体nk细胞组合物和使用方法
WO2024140836A1 (zh) 靶向nkg2d配体的融合蛋白与嵌合抗原受体细胞的组合及其用途
US20240216432A1 (en) Anti-flt3 antibodies, cars, car t cells and methods of use
Drabble Enhancing CAR T Cell Therapy with NKG2D CAR NK Cells to Improve Efficacy Against B cell Leukaemia
WO2024169985A1 (zh) 靶向HER2/p95HER2的P329G抗体及其与嵌合抗原受体细胞的组合和应用
HK1239703A1 (en) Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
HK40102796A (en) Cell injury inducing therapeutic drug for use in cancer therapy
HK1229842A1 (en) Novel synthetic biology-based adcc technology

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170707

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201207

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230118

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240125

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240329

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240329

End annual number: 3

Start annual number: 1

PG1601 Publication of registration